Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
179M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
46.1M
-
Shares change
-
+4.39M
-
Total reported value, excl. options
-
$676M
-
Value change
-
+$67.1M
-
Number of buys
-
53
-
Number of sells
-
-26
-
Price
-
$14.65
Significant Holders of Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) as of Q2 2023
90 filings reported holding PRME - Prime Medicine, Inc. - Common Stock, $0.00001 par value as of Q2 2023.
Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.1M shares
of 179M outstanding shares and own 25.81% of the company stock.
Largest 10 shareholders include Alphabet Inc. (11.9M shares), FMR LLC (4.04M shares), VANGUARD GROUP INC (3.33M shares), Nikko Asset Management Americas, Inc. (3.06M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.06M shares), BlackRock Inc. (2.89M shares), ARK Investment Management LLC (2.45M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.33M shares), FIL Ltd (1.81M shares), and MWG Management Ltd. (1.79M shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.